MARK 1A Series: Percutaneous Microwave Ablation for Patients With Lung Tumor(s)
Does lung ablation improve clinical outcomes for patients deemed to be surgically high-risk?
Checked against the public recordLast updated Oct 4, 2023 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- Mayo Clinic
- Interventions being studied
- Procedure: Microwave ablation
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Subject must be at least 18 years old. * Subject is able to understand the study procedures and provide informed consent. * Subject is willing and able to complete the entire study as specified in the protocol, including the follow-up visits. * Subject has lung lesion that is biopsy-proven cancer (of any type) or suspicious, with confirmation at the time of the procedure. * Lung lesion(s) are reachable/treatable per clinician opinion. * Subject can have other location of disease if it is controlled, or there are plans for control. * Subject has 1 or more lung nodules (not more than 10), that have a mean diameter \<3 cm on axial CT scan. * Life expectancy ≥6 months Exclusion Criteria: * Subject is pregnant or breast feeding. * Subject has a significant clinical disease or condition, e.g. cardiovascular, respiratory, gastrointestinal, renal, hepatic, hematological, psychiatric or neurologic that would preclude enrollment, as determined by the primary investigator. * Subject has another location of disease that is not controlled, and there are no plans for control. * Subject has more than 10 lung nodules.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Mayo ClinicRochester, Minnesota
- Mayo Clinic in RochesterRochester, Minnesota
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 4, 2023. Always confirm current availability with the study team.